Panel Backs Limited New Olaparib Use in Prostate Cancer

An expert panel recommended restricting the expanded first-line indication to patients whose metastatic castration-resistant prostate tumors have BRCA mutations.
Medscape Medical News

source https://www.medscape.com/viewarticle/991408?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?